Faruqi & Faruqi, LLP Investigates Claims on Behalf of Utilized Therapeutics Traders By Investing.com
Faruqi & Faruqi LLP Securities Litigation Accomplice James (Josh) Wilson Encourages Traders…
Verve Therapeutics Proclaims Incentive Grants Underneath Nasdaq Itemizing Rule 5635(c)(4) By Investing.com
BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage firm…
Kessler Topaz Meltzer & Test, LLP Reminds Kyverna Therapeutics, Inc. Shareholders of Securities Fraud Class Motion Lawsuit Deadline By Investing.com
Radnor, PA--(Newsfile Corp. - January 3, 2025) - The legislation agency of…
Utilized Therapeutics, Inc. Buyers are alerted that the corporate has been sued for securities fraud and are urged to contact BFA earlier than the approaching courtroom deadline. By Investing.com
(Newsfile Corp. - January 2, 2025) - Main securities regulation agency Bleichmar…
ROSEN, COMPETENT INVESTOR ADVISOR, Encourages Buyers in Utilized Therapeutics, Inc. to Get hold of Counsel Earlier than an Vital Securities Class Motion Deadline
New York, New York--(Newsfile Corp. - January 1, 2025) - FOR WHAT:…
Edgewise Therapeutics Chief Scientific Officer Sells $2.74 Million in Inventory By Investing.com
Russell Alan J, Chief Scientific Officer of Edgewise Therapeutics, Inc. (NASDAQ: EWTX),…
Sangamo Therapeutics shares collapse as Pfizer ends hemophilia drug pact
Good sale / NurPhoto through Getty Photographs Shares of Sangamo Therapeutics misplaced…
Sangamo Therapeutics shares plunge as Pfizer ends hemophilia gene remedy pact
Sangamo Therapeutics shares plunge as Pfizer ends hemophilia gene remedy pact Monday,…
Kuehn Regulation Encourages Akero Therapeutics, Inc. Traders to Contact a Regulation Agency By Investing.com
New York, New York--(Newsfile Corp. - December 30, 2024) - Kuehn Regulation,…
Kessler Topaz Meltzer & Test, LLP reminds Kyverna Therapeutics, Inc. (KYTX) traders {that a} securities fraud class motion lawsuit has been filed by Investing.com
Radnor, PA--(Newsfile Corp. - December 29, 2024) - The legislation agency of…
